Personalis' (PSNL) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "buy" rating for Personalis' stock (NASDAQ:PSNL) with a target price of $8.50, indicating a potential upside of 62.21% from the previous close.
• Personalis recently reported a quarterly EPS of ($0.23), which exceeded analysts' expectations, but its revenue was $17.20 million, falling short of the $20.12 million forecast.
• Institutional investors hold a significant portion of Personalis' stock, with hedge funds and other entities owning 61.91% of the company, reflecting strong interest from large investors.

Personalis (NASDAQ:PSNL - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $8.50 price target on the stock. HC Wainwright's target price points to a potential upside of 62.21% from the company's previous close.

PSNL has been the topic of a number of other research reports. Guggenheim began coverage on Personalis in a report on Thursday, May 15th. They set a "buy" rating and a $6.00 target price on the stock. BTIG Research set a $6.00 target price on Personalis in a report on Wednesday, August 6th. Finally, Wall Street Zen downgraded Personalis from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $7.42.

Personalis Price Performance

PSNL opened at $5.24 on Monday. The business has a 50 day simple moving average of $5.65 and a two-hundred day simple moving average of $4.83. The firm has a market capitalization of $464.68 million, a price-to-earnings ratio of -4.09 and a beta of 1.76. Personalis has a one year low of $2.83 and a one year high of $7.79.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts expect that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Trading of Personalis

Several hedge funds and other institutional investors have recently made changes to their positions in PSNL. Lightspeed Management Company L.L.C. purchased a new stake in Personalis during the 4th quarter valued at $47,169,000. ARK Investment Management LLC boosted its stake in Personalis by 6.1% during the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock valued at $25,231,000 after purchasing an additional 412,762 shares during the last quarter. AIGH Capital Management LLC boosted its stake in Personalis by 4.5% during the 1st quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company's stock valued at $13,931,000 after purchasing an additional 169,884 shares during the last quarter. Aberdeen Group plc boosted its stake in Personalis by 3.2% during the 2nd quarter. Aberdeen Group plc now owns 1,759,497 shares of the company's stock valued at $11,542,000 after purchasing an additional 54,713 shares during the last quarter. Finally, Blue Water Life Science Advisors LP boosted its stake in Personalis by 42.6% during the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company's stock valued at $10,997,000 after purchasing an additional 500,900 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.